Clinical-trials tracker
How much human testing each peptide is actually getting: total registered studies, how many are recruiting, how many are still active, and how many have finished — with the highest phase reached. The metabolic peptides dominate; most research peptides have a handful of trials or none.
Data as of July 20, 2026 ·15,552 trials across 78 compounds
- 15,552trials tracked
- 78compounds in trials
- 1,406recruiting now
- 40notable open studies
Type
Activity
78 compounds shown
| Compound | Total | Recruiting | Active | Completed | Top phase |
|---|---|---|---|---|---|
| L-TyrosineAmino acid | 2,057 | 60 | 28 | 11 | Phase 4 |
| L-PhenylalanineAmino acid | 1,065 | 51 | 22 | 20 | Phase 4 |
| GABAAmino acid | 1,045 | 43 | 5 | 45 | Phase 4 |
| L-SerineAmino acid | 822 | 60 | 11 | 18 | Phase 4 |
| L-ArginineAmino acid | 771 | 45 | 13 | 37 | Phase 4 |
| SemaglutidePeptide · Incretin / metabolic | 716 | 61 | 14 | 23 | Phase 4 |
| L-CysteineAmino acid | 714 | 49 | 13 | 33 | Phase 4 |
| NAC (N-acetylcysteine)Amino acid | 665 | 48 | 17 | 29 | Phase 4 |
| L-DOPA (levodopa)Amino acid | 610 | 39 | 16 | 43 | Phase 4 |
| LiraglutidePeptide · Incretin / metabolic | 513 | 33 | 11 | 44 | Phase 4 |
| L-ValineAmino acid | 438 | 43 | 7 | 33 | Phase 4 |
| ExenatidePeptide · Incretin / metabolic | 377 | 13 | 7 | 56 | Phase 4 |
| AlanineAmino acid | 359 | 49 | 22 | 23 | Phase 4 |
| CreatineAmino acid | 347 | 51 | 7 | 39 | Phase 4 |
| L-LeucineAmino acid | 313 | 56 | 10 | 26 | Phase 3 |
| L-Carnitine / ALCARAmino acid | 306 | 28 | 13 | 42 | Phase 4 |
| L-GlutamineAmino acid | 286 | 34 | 3 | 39 | Phase 4 |
| GlutathioneAmino acid | 266 | 34 | 14 | 39 | Phase 4 |
| TirzepatidePeptide · Incretin / metabolic | 261 | 69 | 11 | 20 | Phase 4 |
| NAD+Peptide · Longevity / mitochondrial | 259 | 58 | 6 | 32 | Phase 4 |
| GlycineAmino acid | 240 | 29 | 9 | 45 | Phase 4 |
| L-LysineAmino acid | 214 | 27 | 13 | 41 | Phase 4 |
| L-MethionineAmino acid | 210 | 27 | 12 | 41 | Phase 4 |
| HomocysteineAmino acid | 185 | 20 | 1 | 53 | Phase 4 |
| L-ProlineAmino acid | 173 | 24 | 4 | 42 | Phase 4 |
| L-TryptophanAmino acid | 170 | 31 | 7 | 47 | Phase 4 |
| L-CitrullineAmino acid | 158 | 19 | 2 | 60 | Phase 4 |
| L-Glutamic acidAmino acid | 158 | 16 | 18 | 37 | Phase 4 |
| TaurineAmino acid | 151 | 22 | 6 | 51 | Phase 4 |
| L-HistidineAmino acid | 141 | 27 | 7 | 40 | Phase 4 |
| DulaglutidePeptide · Incretin / metabolic | 139 | 18 | 7 | 62 | Phase 4 |
| L-OrnithineAmino acid | 124 | 18 | 10 | 50 | Phase 4 |
| L-ThreonineAmino acid | 113 | 23 | 8 | 44 | Phase 4 |
| Aspartic acidAmino acid | 104 | 14 | 7 | 58 | Phase 4 |
| Beta-alanineAmino acid | 83 | 10 | 7 | 53 | Phase 4 |
| Betaine (TMG)Amino acid | 80 | 14 | 4 | 46 | Phase 4 |
| SAMeAmino acid | 69 | 11 | 3 | 41 | Phase 4 |
| Thymosin alpha-1Peptide · Immune / antimicrobial | 63 | 18 | 3 | 22 | Phase 4 |
| L-IsoleucineAmino acid | 60 | 11 | 4 | 31 | Phase 4 |
| L-TheanineAmino acid | 54 | 10 | 1 | 40 | Phase 4 |
| CarnosineAmino acid | 53 | 3 | 1 | 36 | Phase 4 |
| OrforglipronPeptide · Incretin / metabolic | 48 | 9 | 8 | 31 | Phase 3 |
| CagrilintidePeptide · Incretin / metabolic | 42 | 11 | 8 | 21 | Phase 3 |
| CerebrolysinPeptide · Nootropic / mental-health | 42 | 8 | 1 | 19 | Phase 4 |
| MazdutidePeptide · Incretin / metabolic | 34 | 14 | 3 | 17 | Phase 4 |
| RetatrutidePeptide · Incretin / metabolic | 33 | 3 | 11 | 19 | Phase 3 |
| CagriSemaPeptide · Incretin / metabolic | 30 | 6 | 5 | 17 | Phase 3 |
| LarazotidePeptide · Healing / recovery | 29 | 1 | 3 | 21 | Phase 3 |
| 5-HTPAmino acid | 28 | 6 | 0 | 18 | Phase 4 |
| SermorelinPeptide · GH secretagogues | 27 | 1 | 0 | 21 | Phase 4 |
| SetmelanotidePeptide · Melanocortin | 27 | 3 | 3 | 18 | Phase 4 |
| SurvodutidePeptide · Incretin / metabolic | 24 | 5 | 2 | 17 | Phase 3 |
| TesamorelinPeptide · GH secretagogues | 24 | 3 | 0 | 14 | Phase 4 |
| Melanotan I (afamelanotide)Peptide · Melanocortin | 23 | 0 | 1 | 18 | Phase 3 |
| DefensinsPeptide · Immune / antimicrobial | 22 | 0 | 0 | 7 | Phase 4 |
| SS-31 (elamipretide)Peptide · Longevity / mitochondrial | 21 | 2 | 2 | 14 | Phase 4 |
| LL-37Peptide · Immune / antimicrobial | 20 | 2 | 0 | 12 | Phase 3 |
| VIP (vasoactive intestinal peptide)Peptide · Healing / recovery | 19 | 0 | 1 | 13 | Phase 4 |
| Thymosin beta-4Peptide · Healing / recovery | 18 | 3 | 0 | 11 | Phase 3 |
| AsparagineAmino acid | 14 | 1 | 2 | 9 | Phase 3 |
| FollistatinPeptide · GH secretagogues | 14 | 3 | 0 | 10 | Phase 4 |
| TesofensinePeptide · Incretin / metabolic | 13 | 0 | 0 | 11 | Phase 2 |
| Citrulline malateAmino acid | 11 | 0 | 1 | 6 | Phase 2 |
| HydroxyprolineAmino acid | 10 | 0 | 0 | 6 | Phase 4 |
| PT-141 (bremelanotide)Peptide · Melanocortin | 10 | 0 | 1 | 9 | Phase 4 |
| MK-677 (ibutamoren)Peptide · GH secretagogues | 8 | 1 | 0 | 5 | Phase 3 |
| Argireline (acetyl hexapeptide-8)Peptide · Cosmetic / skin | 6 | 0 | 0 | 5 | Phase 3 |
| MOTS-cPeptide · Longevity / mitochondrial | 5 | 3 | 1 | 0 | Phase 2 |
| ARA-290 (cibinetide)Peptide · Healing / recovery | 4 | 0 | 0 | 2 | Phase 2 |
| HumaninPeptide · Longevity / mitochondrial | 3 | 1 | 0 | 1 | N/A |
| BPC-157Peptide · Healing / recovery | 2 | 1 | 0 | 0 | Phase 2 |
| IpamorelinPeptide · GH secretagogues | 2 | 0 | 0 | 2 | Phase 2 |
| SelankPeptide · Nootropic / mental-health | 2 | 0 | 0 | 1 | N/A |
| CJC-1295Peptide · GH secretagogues | 1 | 0 | 0 | 0 | Phase 2 |
| GHK-CuPeptide · Cosmetic / skin | 1 | 1 | 0 | 0 | Phase 2 |
| Melanotan IIPeptide · Melanocortin | 1 | 1 | 0 | 0 | Phase 2 |
| SelenocysteineAmino acid | 1 | 0 | 0 | 1 | Phase 1 |
| TB-500Peptide · Healing / recovery | 1 | 1 | 0 | 0 | Phase 2 |
What's actively recruiting right now
These studies are open and enrolling as of the date above — the leading edge of peptide research. Retatrutide and the other incretin drugs are running large Phase 3 programs; a few research peptides (BPC-157 among them) have small early-phase trials underway. Each links to its ClinicalTrials.gov record.
| Compound | Phase | Status | Study | Sponsor | Primary completion |
|---|---|---|---|---|---|
| L-Arginine | Phase 4 | Enrolling (invitation) | NCT07712328Randomized Controlled Clinical Study on the Prophylactic Intraoperative Use of Desmopressin in Complex Sellar Region Tumors | Zhaoyun Zhang | May 1, 2028 |
| Tirzepatide | Phase 4 | Enrolling (invitation) | NCT07707778Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV | National Taiwan University Clinical Trial Center | Dec 2027 |
| Tirzepatide | Phase 4 | Not yet recruiting | NCT07706088Effect of Tirzepatide on Diabetic Peripheral Sensorimotor Neuropathy | Post Graduate Institute of Medical Education and Research, Chandigarh | Jul 1, 2028 |
| L-Serine | Phase 4 | Recruiting | NCT07145866Varenicline and Accelerated Transcranial Magnetic Stimulation (TMS) for Quitting Nicotine Use (Pilot Study) | Massachusetts General Hospital | Sep 2027 |
| SS-31 (elamipretide) | Phase 4 | Recruiting | NCT07531251Clinical Trial in Patients With Barth Syndrome- 4TAZPower | Stealth BioTherapeutics Inc. | Sep 30, 2029 |
| Tirzepatide | Phase 4 | Not yet recruiting | NCT07697391AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes | The First Affiliated Hospital of Anhui Medical University | Oct 31, 2027 |
| L-Cysteine | Phase 4 | Recruiting | NCT07409727Effect of Acetylcysteine Inhalation on Incidence and Time to Develop Ventilator Associated Pneumonia in Critically Ill Mechanically Ventilated Patients | Cairo University | Mar 2028 |
| NAC (N-acetylcysteine) | Phase 4 | Recruiting | NCT07409727Effect of Acetylcysteine Inhalation on Incidence and Time to Develop Ventilator Associated Pneumonia in Critically Ill Mechanically Ventilated Patients | Cairo University | Mar 2028 |
| Glycine | Phase 4 | Recruiting | NCT07578012Prevention With Ismigen of RTIs in Kids | Lallemand Pharma AG | Mar 2027 |
| L-Serine | Phase 4 | Not yet recruiting | NCT07643493CleaRRAflow: Isotonic Solution vs. TPA for IVH Clearance | David Dornbos | May 31, 2028 |
| Semaglutide | Phase 4 | Recruiting | NCT06003153GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH | Massachusetts General Hospital | May 31, 2027 |
| Tirzepatide | Phase 4 | Recruiting | NCT07247084A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK) | Eli Lilly and Company | Jul 2029 |
| Semaglutide | Phase 4 | Enrolling (invitation) | NCT05371496Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction | Mayo Clinic | Aug 2026 |
| Semaglutide | Phase 4 | Recruiting | NCT06396416Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2 | Western University, Canada | Sep 30, 2026 |
| Setmelanotide | Phase 4 | Recruiting | NCT07674290Real-World Effects of MC4R Agonist Therapy in BBS and Severe Genetic Obesity | Tom Hühne | Dec 31, 2030 |
| L-Phenylalanine | Phase 4 | Recruiting | NCT06433310Understanding the Efficacy of Dietary Supplement on Fungal Mycobiota in Healthy Volunteers: A Pilot Study | Weill Medical College of Cornell University | Dec 17, 2027 |
| Semaglutide | Phase 4 | Not yet recruiting | NCT07592546Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss | Alain Dagher | Dec 1, 2028 |
| Semaglutide | Phase 4 | Recruiting | NCT07017270Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis | Unity Health Toronto | Jul 2027 |
| L-Phenylalanine | Phase 4 | Recruiting | NCT07044232NICardipine for Fast Achievement of Systolic BP Targets in ICH | Aarhus University Hospital | Sep 30, 2026 |
| L-Tyrosine | Phase 4 | Recruiting | NCT07044232NICardipine for Fast Achievement of Systolic BP Targets in ICH | Aarhus University Hospital | Sep 30, 2026 |
| Mazdutide | Phase 4 | Not yet recruiting | NCT07657676Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity | China National Center for Cardiovascular Diseases | Oct 31, 2027 |
| L-Phenylalanine | Phase 4 | Recruiting | NCT07477691Immune Modulation During Palynziq® Treatment in Adults (IMPALA) | BioMarin Pharmaceutical | Sep 30, 2027 |
| Mazdutide | Phase 4 | Not yet recruiting | NCT07654062Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE) | Shandong Provincial Hospital | Jun 2028 |
| GABA | Phase 4 | Recruiting | NCT06852469Computational Assessment of GABA Receptor Modulation in PTSD | VA Office of Research and Development | Jun 30, 2029 |
| Semaglutide | Phase 4 | Not yet recruiting | NCT06977438GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way Forward | University of Minnesota | Jan 31, 2031 |
| L-Citrulline | Phase 4 | Recruiting | NCT07642505L-Citrulline and Tadalafil for Mild to Moderate Erectile Dysfunction | Beni-Suef University | Nov 2026 |
| L-Serine | Phase 4 | Not yet recruiting | NCT07644923Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation | NYU Langone Health | Aug 1, 2028 |
| Tirzepatide | Phase 4 | Recruiting | NCT07257484Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors | Weill Medical College of Cornell University | Dec 3, 2027 |
| L-Carnitine / ALCAR | Phase 4 | Not yet recruiting | NCT07642076Evaluation of the Clinical Impact of Adjunctive L-carnitine Therapy in Critically Ill Hepatic Patients Admitted to Intensive Care Unit | Beni-Suef University | Dec 2026 |
| Tirzepatide | Phase 4 | Recruiting | NCT06864026A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA) | Eli Lilly and Company | Nov 2027 |
| Semaglutide | Phase 4 | Not yet recruiting | NCT07462663SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial Cancer | Hospital Universitari de Bellvitge | Apr 2031 |
| Glutathione | Phase 4 | Recruiting | NCT07634991To Evaluate the Efficacy and Safety of N-acetyl Cysteine Administration in Patients With Diabetic Retinopathy | Ain Shams University | Dec 30, 2026 |
| L-Cysteine | Phase 4 | Recruiting | NCT07634991To Evaluate the Efficacy and Safety of N-acetyl Cysteine Administration in Patients With Diabetic Retinopathy | Ain Shams University | Dec 30, 2026 |
| NAC (N-acetylcysteine) | Phase 4 | Recruiting | NCT07634991To Evaluate the Efficacy and Safety of N-acetyl Cysteine Administration in Patients With Diabetic Retinopathy | Ain Shams University | Dec 30, 2026 |
| Tirzepatide | Phase 4 | Recruiting | NCT07218445The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity | Mayo Clinic | Sep 18, 2027 |
| Tirzepatide | Phase 4 | Not yet recruiting | NCT07630454Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF | Yunlong Wang | Aug 1, 2029 |
| L-Serine | Phase 4 | Not yet recruiting | NCT07518303Nafamostat Mesylate Versus Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury | Jianfeng Xie | Jun 10, 2028 |
| Tirzepatide | Phase 4 | Recruiting | NCT06857942A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO) | Eli Lilly and Company | May 2028 |
| Tirzepatide | Phase 4 | Recruiting | NCT07154719GLP-1R Actions on Muscle and the Skeleton | Pennington Biomedical Research Center | Feb 1, 2027 |
| L-Arginine | Phase 4 | Recruiting | NCT07604896Evaluating the Efficacy and Safety of Lecanemab in Alzheimer's Disease Through Multi-omics Approachs | First Affiliated Hospital of Wenzhou Medical University | Dec 31, 2027 |
How this tracker is built
Counts come from the ClinicalTrials.gov API (v2), queried by intervention name for each compound. Total is every registered study; recruitingcounts those actively enrolling; active means underway but no longer recruiting; completed means the study has finished. A compound with zero trials simply isn't listed here — an honest gap, not a hidden row. The table refreshes whenever the site rebuilds, so the "as of" date is the real freshness.